NVCR long Like the volume and the high wave indecision candle.
Great spacing between the moving averages, offering great risk reward.
Looking for a pull back to get in with a limit buy
−1.95USD
−207.04 MUSD
509.34 MUSD
96.28 M
About NovoCure Limited
Sector
Industry
CEO
Asaf Danziger
Website
Headquarters
St. Helier
Employees (FY)
1.45 K
Founded
2000
ISIN
JE00BYSS4X48
FIGI
BBG009XW8PY2
NovoCure Ltd. is an oncology company which engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. Its platform is called the Tumor Treating Field which uses electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. The company was founded by Yoram Palti in 2000 and is headquartered in St. Helier, Jersey.
NVCRNuovo cure consolidating under 200 dma , but above 65 ema , Pradeep Bonde says 65 ema cross is better then 200 ema
Long short term / short long termKeeping it simple here. Given the current market conditions, it could play out in a h&S pattern with a target of around 15 bucks. What do you think?
NVCR ready to go on an extended run Initial Target by Apr 14 = 99
Target Range by 5/20/2022 = 108-116
Upcoming earnings as a catalyst. Bullish Momentum for pre-earnings run up.
Kept the chart simple but a lot of bullish aspects at play here, to name a few:
- ready for markup coming off an accumulation phase
- completes wave 5 corre
NVCR primed for an extended runKept the chart simple but there are a lot of bullish aspects at play here:
- ready for markup after an accumulation phase
- coming off a wave 5 correction apprx. 0.786 off the highs last June
- looking at weekly chart you’ll see a larger running flat structure
- earnings as a catalyst and overall
NVCR - SwingSwing trade - longer term. Could enter between 90/92 or wait for more bullish momentum and catch it on the pullback.
NVCRWatching, in a heavy buy zone, ADX/DI about to cross bullish with RSI divregence. Hasnt been able to close above the 20 EMA since JUN, that will be my final buy trigger. Huge potential.
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of NVCR is 12.05 USD — it has decreased by 3.29% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange NovoCure Limited stocks are traded under the ticker NVCR.
NovoCure Limited is going to release the next earnings report on May 2, 2024. Keep track of upcoming events with our Earnings Calendar.
One year price forecast for NovoCure Limited has a max estimate of 42.00 USD and a min estimate of 15.00 USD.
NVCR earnings for the last quarter are −0.46 USD whereas the estimation was −0.53 USD which accounts for 12.38% surprise. Estimated earnings for the next quarter are −0.52 USD. See more details about NovoCure Limited earnings.
NovoCure Limited revenue for the last quarter amounts to 127.32 M USD despite the estimated figure of 128.75 M USD. In the next quarter revenue is expected to reach 133.80 M USD.
Yes, you can track NovoCure Limited financials in yearly and quarterly reports right on TradingView.
NVCR stock has fallen by 16.78% compared to the previous week, the month change is a 14.23% fall, over the last year NovoCure Limited has showed a 81.33% decrease.
Like other stocks, NVCR shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade NovoCure Limited stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 18, 2024, the company has 1.45 K employees. See our rating of the largest employees — is NovoCure Limited on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. NovoCure Limited EBITDA is −221.42 M USD, and current EBITDA margin is −43.47%. See more stats in NovoCure Limited financial statements.